UK markets closed

LIDDS AB (publ) (LIDDS.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
9.49+0.37 (+4.06%)
At close: 05:22PM CET
Full screen
Previous close9.12
Open9.40
Bid9.01 x 0
Ask9.48 x 0
Day's range8.78 - 9.49
52-week range8.70 - 19.00
Volume50,566
Avg. volume81,107
Market cap322.563M
Beta (5Y monthly)0.53
PE ratio (TTM)N/A
EPS (TTM)-1.32
Earnings date24 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est33.00
  • Globe Newswire

    LIDDS presents at Redeye Fight Cancer Seminar

    UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Nina Herne will participate at Redeye Fight Cancer Seminar on January 20, 2022. Nina Herne, CEO of LIDDS, will present at 15.45 CET on January 20, 2022, at Redeye Fight Cancer Seminar, an annually recurring event where Redeye invites some of the leading Nordic companies in this field to give updates on the coming year. The event is held between 09.00 and 16.00 and is broadcast on redeye.se/events. Please register at www.lyyti.in/watch-live-b

  • Globe Newswire

    LIDDS announces successful stage 1 in R&D project

    UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the R&D project with Johnson & Johnson Enterprise Innovation Inc. has progressed into next phase. “On the back of a strong collaboration, we have generetad promising data which led to a unianimous decision by the joint research committee to move the project into the next stage. At LIDDS, we aim to improve outcomes for those fighting cancer by diminishing severe side effects and enhancing efficacy. The completion of Stage 1 is a key milestone

  • Globe Newswire

    LIDDS announces positive topline results from the phase I dose-escalating study of NanoZolid®-formulated docetaxel

    UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the systemic exposure of docetaxel after treating solid tumors with NanoZolid®-docetaxel is low and that the study demonstrated activity in both injected lesions and in systemic inflammatory markers. The results support further development of NanoZolid®-docetaxel. In October 2021, LIDDS announced the closing of the NZ-DTX-001 Phase I study. It was demonstrated that NanoZolid® in combination with docetaxel was safe and well tolerated, reachin